AU2002217430A1 - Use of coumarin or its hydroxy derivative for the treatment of medium or severe vascular and/or lymphatic edema - Google Patents

Use of coumarin or its hydroxy derivative for the treatment of medium or severe vascular and/or lymphatic edema

Info

Publication number
AU2002217430A1
AU2002217430A1 AU2002217430A AU2002217430A AU2002217430A1 AU 2002217430 A1 AU2002217430 A1 AU 2002217430A1 AU 2002217430 A AU2002217430 A AU 2002217430A AU 2002217430 A AU2002217430 A AU 2002217430A AU 2002217430 A1 AU2002217430 A1 AU 2002217430A1
Authority
AU
Australia
Prior art keywords
coumarin
treatment
medium
hydroxy derivative
severe vascular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002217430A
Other languages
English (en)
Inventor
Massimo Chimenti
Andrea Fratter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MAC PHARMA Sas
Original Assignee
Mac Pharma S A S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mac Pharma S A S filed Critical Mac Pharma S A S
Publication of AU2002217430A1 publication Critical patent/AU2002217430A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2002217430A 2001-12-04 2001-12-04 Use of coumarin or its hydroxy derivative for the treatment of medium or severe vascular and/or lymphatic edema Abandoned AU2002217430A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IT2001/000613 WO2003047566A1 (en) 2001-12-04 2001-12-04 Use of coumarin or its hydroxy derivative for the treatment of medium or severe vascular and/or lymphatic edema

Publications (1)

Publication Number Publication Date
AU2002217430A1 true AU2002217430A1 (en) 2003-06-17

Family

ID=11133762

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002217430A Abandoned AU2002217430A1 (en) 2001-12-04 2001-12-04 Use of coumarin or its hydroxy derivative for the treatment of medium or severe vascular and/or lymphatic edema

Country Status (6)

Country Link
EP (1) EP1450788B8 (de)
AT (1) ATE304847T1 (de)
AU (1) AU2002217430A1 (de)
DE (1) DE60113569T2 (de)
ES (1) ES2249391T3 (de)
WO (1) WO2003047566A1 (de)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0172893A4 (de) * 1984-03-01 1987-05-13 John Royle Casley-Smith Behandlung von ödemen mit hohem proteingehalt bei tieren.
GB2168696B (en) * 1984-12-21 1989-01-11 Boehringer Biochemia Srl Fluoro coumarins as antilymphoedema agents
US4616033A (en) * 1985-03-14 1986-10-07 Lamorna Investments Proprietary Ltd. 7 hydroxy-coumarin as a treatment for high protein oedemas
DE3715990C2 (de) * 1987-05-13 1993-10-28 Schaper & Bruemmer Gmbh Verwendung von Cumarin und 7-Hydroxy-cumarin
ATE200979T1 (de) * 1994-02-18 2001-05-15 Drossapharm Ag Transdermales therapeutisches system
GB9722600D0 (en) * 1997-10-24 1997-12-24 Bio Monde Holdings Internation Pharmaceutical compositon

Also Published As

Publication number Publication date
DE60113569D1 (de) 2006-02-02
EP1450788B8 (de) 2006-05-03
ES2249391T3 (es) 2006-04-01
DE60113569T2 (de) 2006-05-04
EP1450788B1 (de) 2005-09-21
ATE304847T1 (de) 2005-10-15
WO2003047566A1 (en) 2003-06-12
EP1450788A1 (de) 2004-09-01

Similar Documents

Publication Publication Date Title
AU2002236765A1 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
EP1268412B8 (de) Sulfonamido-substituierte verbrückte bicycloalkylderivative
IL122546A0 (en) Use of a combination of ritonavir and a drug metabolized by cytochrome p450 monooxygenase in the preparation of medicaments and pharmaceutical compositions containing the combination
AU2002239748A1 (en) Use of tocopherol, metabolites or derivatives thereof or flavonoid metabolites or derivatives thereof in the manufacture of a medicament for the treatment of tissue ischemia
IL136839A0 (en) Pharmaceutical compositions comprising cannabidiol derivatives
NZ514574A (en) Novel method of treatment
FI972793A (fi) Nebivololin käyttö antiaterogeenisenä aineena
NZ279062A (en) Use of phenylazosalicylic acid derivatives for treatment/prevention of colon cancer
AU7031500A (en) Therapeutic quinazoline compounds
EP1232757A4 (de) Mittel für erkrankungen assoziert mit knochensubstanzverlust
HK1043368A1 (en) Novel derivatives of flavones, xanthones and coumarins
MXPA03010761A (es) Combinaciones farmaceuticas.
WO2000045800A3 (en) Immunosurpressive effects of pteridine derivatives
NZ515339A (en) Use of macrolide compounds for the treatment of dry eye
ES2191449T3 (es) Derivados de ciclopentabenzofurano y su uso.
AU7862401A (en) Pharmaceutical compostion comprising trkaig2 for use in the prevention and/or treatment of cancer
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
TNSN03043A1 (en) 2h-1 benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof
AU2162202A (en) Antitumor therapy comprising distamycin derivatives
CA2461117A1 (en) Botulinus toxin for treatment of body odour
EP1450788B8 (de) Verwendung von cumarin oder seines hydroxy-derivats zur behandlung von mittelschwerem oder schwerem gefäss- und/oder lymphödem
WO2001060343A3 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und/oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
WO2002034244A3 (en) A combination comprising camptothecin and a stilbene derivative for the treatment of cancer
HK1075390A1 (en) Citalopram for the treatment of elevated blood pressure
WO2001060326A3 (fr) Composition cosmetique ou pharmaceutique contenant une lactone sesquiterpenique

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase